Liverty TIPS Stent Graft
Bard Peripheral Vascular, Inc. · Decision date Sep 25, 2026
What did the FDA approve?
FDA records P250050 as an original PMA application. The recorded decision is approval, dated Sep 25, 2026.
FDA approval order statement
Approval for the Liverty TIPS Stent Graft. The device is indicated for the treatment of complications of portal hypertension
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 25, 2026
Regulatory record facts
- Identifier
- P250050
- Regulatory pathway
- Premarket approval application
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- MIR
- Decision code
- APPR
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS.
- Applicant
- Bard Peripheral Vascular, Inc.
- Product code
- MIR
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250050 received
Application receipt date recorded by FDA.
P250050 · FDA decision
APPR
P250050/S001 · Related supplement
Liverty TIPS Stent Graft
Timeline entries are records held by MedtechLedger for P250050. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250050
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Liverty TIPS Stent GraftP250050/S001 | Bard Peripheral Vascular, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Bard Peripheral Vascular, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1625 W. 3rd St., Tempe, AZ, 85281
Sources and methodology
- Original FDA record: P250050
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records